✦ LIBER ✦

P-629 A phase I study of erlotinib (TarcevaTM) monotherapy in Japanese patients with non-small cell lung cancer and other solid tumors

✍ Scribed by Atsushi, Horiike; Yamada, Yasuhide; Yamamoto, Noboru; Shimoyama, Tatsu; Murakami, Haruyasu; Fujisake, Yasuhito; Takayama, Kyoko; Sakamoto, Terumi; Tamura, Tomohide

Book ID: 118572324
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 193 KB
Volume: 41
Category: Article
ISSN: 0169-5002
DOI: 10.1016/s0169-5002(03)92596-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P-611 Final results from a phase II stud

P-611 Final results from a phase II study of erlotinib (TarcevaTM) monotherapy in patients with advanced non-small cell lung cancer following failure of platinum-based chemotherapy

✍ Perez-Soler, Roman; Chachoua, Abraham; Huberman, Mark; Karp, Daniel; Rigas, Jame 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 369 KB

Phase I study of autologous dendritic ce

Phase I study of autologous dendritic cell tumor vaccine in patients with non-small cell lung cancer

✍ Um, Soo-Jung; Choi, Young Jin; Shin, Ho-Jin; Son, Cheol Hun; Park, You-Soo; Roh, 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 420 KB

Association between poor performance sta

Association between poor performance status and risk for toxicity during erlotinib monotherapy in Japanese patients with non-small cell lung cancer: Okayama Lung Cancer Study Group experience

✍ Hotta, Katsuyuki; Kiura, Katsuyuki; Takigawa, Nagio; Suzuki, Etsuji; Yoshioka, H 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 132 KB

Phase I Study of Navitoclax (ABT-263), a

Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors

✍ Gandhi, L.; Camidge, D. R.; Ribeiro de Oliveira, M.; Bonomi, P.; Gandara, D.; Kh 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 299 KB

Phase I Study of Navitoclax (ABT-263), a

Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors

✍ Gandhi, L.; Camidge, D. R.; Ribeiro de Oliveira, M.; Bonomi, P.; Gandara, D.; Kh 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 299 KB

## Purpose Resistance to chemotherapy-induced apoptosis represents a major obstacle to cancer control. Overexpression of Bcl-2 is seen in multiple tumor types and targeting Bcl-2 may provide therapeutic benefit. A phase I study of navitoclax, a novel inhibitor of Bcl-2 family proteins, was conduct

A phase I study of sorafenib and vorinos

A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer

✍ A. Dasari, L. Gore, W. A. Messersmith, S. Diab, A. Jimeno, C. D. Weekes, K. D. L 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 266 KB